Priority Date: 29.07.11 (EP 20110305999)

COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE AND RITUXIMAB

  • Application ID: EP12740174
  • Status: GRANT OF PATENT INTENDED

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
1080.35
2 offices
active in Legal Services
no operation time available
2 offices
Technology Company
no operation time available
2 offices
Technology Company

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 190 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 29.07.2011 - Priority Date (EP 20110305999)
  • 07.02.2013 - Publication A1 (WO2013017540)
  • 04.06.2014 - Publication A1 (EP2736534)